Michael Torres: This review is getting a lot of play

Michael Torres, PhD in Cancer Bio at UT Southwestern News, shared on X/Twitter:

“Homogeneous multi-payload antibody–drug conjugates | This review is getting a lot of play. Happy to see the ⁦CrossBridge Bio tech flagged as a ‘notable work demonstrating greater benefit compared to co-administration of the single ADC’.

Now all we need to do is leverage the great resources around such as David S. Hong, Martin Dietrich, Paolo Tarantino, MD Anderson Cancer Center and more to get this to patients as soon as we can!

It’s not lost on us that one of the authors is at flagship so wouldn’t be surprised…have they done an ADC co, yet?”

Source: Michael Torres/X